论文部分内容阅读
目的 :评估尿核基质蛋白 2 2 (NMP2 2 )测定作为尿路上皮癌肿瘤标记物的临床应用价值。方法 :应用免疫酶标记法 (ELISA)检测 58例尿路上皮癌、32例良性泌尿系疾病、1 8例其他恶性肿瘤和 2 0例健康志愿者尿中 NMP2 2水平。尿路上皮癌组中有 2 9例患者在术后 5～ 7d再次检测其尿 NMP2 2。结果 :尿路上皮癌组的尿 NMP2 2平均为 2 9.4× 1 0 3u/L,明显高于良性泌尿系疾病组 (1 0 .1× 1 0 3u/L )、其他恶性肿瘤组 (8.6× 1 0 3u/L)和健康志愿者组 (5.7× 1 0 3u/L) (P <0 .0 0 1 ) ;尿路上皮癌患者尿 NMP2 2随肿瘤病理分级的递增而升高 ;复发病例 (46.9× 1 0 3u/L )高于初发病例 (2 1 .3× 1 0 3u/L ) (P <0 .0 1 ) ;2 9例尿路上皮癌患者术后复测尿 NMP2 2 ,结果较术前明显下降。结论 :尿 NMP2 2作为尿路上皮癌的肿瘤标记物具有较高的特异性 ,并可在一定程度上反应肿瘤的恶性程度和预后。
Objective: To evaluate the clinical value of determination of urine matrix protein 2 2 (NMP2 2) as a tumor marker for urothelial cancer. Methods: Urinary NMP2 2 levels were detected in 58 cases of urothelial carcinoma, 32 cases of benign urological diseases, 18 cases of other malignant tumors and 20 healthy volunteers by enzyme-linked immunosorbent assay (ELISA). Twenty-nine patients in the urothelial carcinoma group were tested for urinary NMP2 2 again 5 to 7 days after surgery. Results: The average urinary NMP2 2 in urothelial carcinoma was 2 9.4 × 10 3 u / L, which was significantly higher than that in benign urological diseases (10.1 × 10 3 u / L) and in other malignant tumors (8.6 × The urinary NMP2 2 levels in urothelial cancer patients increased with the increase of tumor pathological grade. The recurrence rate of patients with urothelial cancer was higher than that of healthy volunteers (5.7 × 10 3 u / L) (P <0.01) (46.9 × 10 3u / L) was higher than that of the initial cases (21.3 × 10 3u / L) (P <0.01), and 29 cases of urothelial carcinoma with postoperative urinary NMP 2 2 , The results decreased significantly compared with preoperative. CONCLUSION: Urinary NMP2 2 has a high specificity as a tumor marker for urothelial carcinoma and can reflect the degree of malignancy and prognosis of the tumor to a certain extent.